Please replace the paragraph beginning at page 2, line 1, with the following rewritten paragraph:

--Immunoprecipitation of HUVEC detergent lysates with anti-CD39 mAb resulted in complete capture of cell-associated ADPase activity, suggesting that CD39 is the only ecto-ADPase on endothelial cells (Marcus et al., *J. Clin. Invest.* 99:1351, 1997). In the same study, COS cell transfectants expressing recombinant CD39 at the cell surface totally inhibited ADP-induced platelet aggregation. Thus, CD39 plays a prominent role in thromboregulation (*see also,* Gayle et al., *J. Clin. Invest.*, 101:1851, 1998; WO96/30532).
--

In the Claims

Cancel Claims 8 through 18.

Add new Claims 20 to 41.

--20. A method according to Claim 1 wherein the soluble CD39 polypeptide has been produced by culturing a recombinant cell that encodes the soluble CD39 polypeptide under conditions permitting expression of the CD39 polypeptide, and recovering the expressed CD39 polypeptide.

21. A method according to Claim 5 wherein the soluble CD39 polypeptide has been produced by culturing a recombinant ~~cell that~~ encodes the soluble CD39 polypeptide under conditions permitting expression of the CD39 polypeptide, and recovering the expressed CD39 polypeptide.

22. The method of claim 20 wherein the recombinant cell comprises a nucleic acid having a sequence selected from the group consisting of:

(a) SEQ ID NO:5; and

(b) DNA sequences which, due to degeneracy of the genetic code, encode the polypeptide encoded by SEQ ID NO:5.

23. The method of claim 21 wherein the recombinant cell comprises a nucleic acid having a sequence selected from the group consisting of:

(a) SEQ ID NO:5; and

(b) DNA sequences which, due to degeneracy of the genetic code, encode the polypeptide encoded by SEQ ID NO:5.

24. The method of claim 20 wherein the recombinant cell comprises a nucleic acid having a sequence selected from the group consisting of:

(a) SEQ ID NO:7; and

(b) DNA sequences which, due to degeneracy of the genetic code, encode the polypeptide encoded by SEQ ID NO:7.

25. The method of claim 21 wherein the recombinant cell comprises a nucleic acid having a sequence selected from the group consisting of:

(a) SEQ ID NO:7; and

(b) DNA sequences which, due to degeneracy of the genetic code, encode the polypeptide encoded by SEQ ID NO:7.

26. The method of Claim 1 wherein the soluble CD39 polypeptide is administered in a composition comprising a pharmaceutically acceptable carrier.

27. The method of Claim 5 wherein the soluble CD39 polypeptide is administered in a composition comprising a pharmaceutically acceptable carrier.

28. The method of Claim 1 wherein the soluble CD39 polypeptide is administered in combination with at least one other antithrombotic or antiplatelet composition.

29. The method of Claim 5 wherein the soluble CD39 polypeptide is administered in combination with at least one other antithrombotic or antiplatelet composition.

30. The method of claim 1 wherein the soluble CD39 polypeptide is administered in combination with aspirin.

31. The method of claim 5 wherein the soluble CD39 polypeptide is administered in combination with aspirin.

32. The method of Claim 1 wherein the soluble CD39 polypeptide is administered parenterally.

33. The method of Claim 5 wherein the soluble CD39 polypeptide is administered parenterally.

34. The method of claim 32 wherein the soluble CD39 polypeptide is administered intravenously.

35. The method of claim 33 wherein the soluble CD39 polypeptide is administered intravenously.

36. The method of Claim 1 wherein the mammal is suffering from unstable angina, myocardial infarction, stroke, coronary artery disease or injury, myocardial infarction, atherosclerosis, peripheral vascular occlusion, preeclampsia, embolism, a platelet-associated ischemic disorder including lung ischemia, coronary ischemia, and cerebral ischemia, a thrombotic disorder including coronary artery thrombosis, cerebral artery thrombosis, intracardiac thrombosis, peripheral artery thrombosis, venous thrombosis, thrombosis and coagulopathy associated with exposure to a foreign or injured tissue surface, deep venous thrombosis (DVT), pulmonary embolism (PE), transient ischemic attack (TIAs), or another related condition where vascular occlusion is the common underlying feature.

37. The method of Claim 5 wherein the mammal is suffering from unstable angina, myocardial infarction, stroke, coronary artery disease or injury, myocardial